Find a Trial

Trial Summary


Protocol No.S1701
StatusOPEN TO ACCRUAL
Principal InvestigatorLoehrer, Patrick
ScopeNational
PhasePhase II
Age GroupAdult
TitleA RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL WITH OR WITHOUT RAMUCIRUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC THYMIC CARCINOMA
DescriptionThis randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Patients must have unresectable thymic carcinoma, that is either locally advanced, recurrent, or metastatic
  • Patients must have a Zubrod performance status of 0 to 2
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesOther Respiratory and Intrathoracic Organs
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu